| Nov 20 |
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
|
| Nov 8 |
Werewolf Therapeutics GAAP EPS of -$0.38 beats by $0.07
|
| Nov 7 |
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
|
| Nov 7 |
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Oct 31 |
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
|
| Oct 20 |
Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks
|
| Oct 4 |
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
|
| Sep 3 |
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 10 |
Werewolf Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Aug 8 |
Werewolf Therapeutics GAAP EPS of -$0.43, revenue of $1.1M
|
